Cell Signaling Technology, Inc. of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies.

(City College of New York) MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents. The work will be performed ...

MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells ...

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies.

Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a ...

SAN FRANCISCO Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests ...

Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a ...

(American Association for Cancer Research) Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and ...

Denosumab inhibits RANKL, a protein involved in bone metabolism, and appears to delay bone metastases onset in patients with prostate cancer, researchers from the Georges Pompidou Hospital, Paris, France, reported at the European Multidisciplinary Cancer Congress 2011, Stockholm, Sweden. The scientists say theirs is the first large-scale human study to ...

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal ...

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled "Monoclonal Antibodies with Enhanced ADCC Function" on April 26, 2011, by the U.S. Patent and Trademark Office.